Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report released on Thursday morning. The brokerage issued a buy rating on the stock.

Trinity Biotech Stock Up 1.0 %

TRIB stock opened at $2.08 on Thursday. The stock’s 50 day simple moving average is $1.96 and its 200 day simple moving average is $2.15. Trinity Biotech has a fifty-two week low of $1.49 and a fifty-two week high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last issued its earnings results on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Trinity Biotech will post -2.17 earnings per share for the current fiscal year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.